Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Prime Medicine (PRME) over the last 5 years, with Dec 2024 value amounting to $195.9 million.

  • Prime Medicine's Cash from Financing Activities rose 275.85% to $144.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.0 million, marking a year-over-year decrease of 23.01%. This contributed to the annual value of $195.9 million for FY2024, which is 29804.73% up from last year.
  • Latest data reveals that Prime Medicine reported Cash from Financing Activities of $195.9 million as of FY2024, which was up 29,804.73% from $655,000 recorded in FY2023.
  • Prime Medicine's Cash from Financing Activities' 5-year high stood at $269.3 million during FY2021, with a 5-year trough of $655,000 in FY2023.
  • Over the past 3 years, Prime Medicine's median Cash from Financing Activities value was $181.5 million (recorded in 2022), while the average stood at $126.0 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 99.64% in 2023, then soared by 29,804.73% in 2024.
  • Over the past 5 years, Prime Medicine's Cash from Financing Activities (Yearly) stood at $34.9 million in 2020, then surged by 670.82% to $269.3 million in 2021, then crashed by 32.60% to $181.5 million in 2022, then slumped by 99.64% to $655,000 in 2023, then surged by 29,804.73% to $195.9 million in 2024.